Volume 6, Issue 1

Boosting the brand image

Vijay Thawani, Priyanka Singh, Heenopama Thakur

pp. 1–2 · DOI: 10.4103/0976-500X.149126 · Published 2015

Phosphodiesterase-4 inhibition with rolipram attenuates hepatocellular injury in hyperinflammation in vivo and in vitro without influencing inflammation and HO-1 expression

Jakob Wollborn, Christian Wunder, Jana Stix, Winfried Neuhaus, Rapahel R. Bruno, Wolfgang Baar, Sven Flemming, Norbert Roewer, Nicolas Schlegel, Martin A.Schick

pp. · DOI: 10.4103/0976-500X.149138 · Published 2015

Objective: To investigate the impact of the phophodiesterase-4 inhibition (PD-4-I) with rolipram on hepatic integrity in lipopolysaccharide (LPS) induced hyperinflammation. Materials and Methods: Liver microcirculation i…

Antibiotic prophylaxis in the prevention of rebleeding in acute variceal hemorrhage: A randomized trial

Ajit Agarwal, Sathasivam Suresh Kumar, Jagdish Sadasivan, Vikram Kate

pp. 83–87 · DOI: 10.4103/0976-500X.149139 · Published 2014

Objective: To assess the role of antibiotic prophylaxis in the prevention of rebleeding in acute variceal hemorrhage. Materials and Methods: A total of 60 patients who underwent endoscopic therapy for bleeding esophageal…

Adverse drug reactions of imatinib in patients with chronic myeloid leukemia: A single-center surveillance study

Jose Francis, Muthiah Palaniappan, Biswajit Dubashi, Suresh Chandra Pradhan, Adithan Chandrasekaran

pp. 30–31 · DOI: 10.4103/0976-500X.149141 · Published 2015

Objective: To monitor the adverse drug reactions (ADRs) associated with imatinib treatment in patients with chronic myeloid leukemia (CML) in a tertiary care hospital. Materials and Methods: The study was carried out by …

The mechanism of antidepressant-like effects of piroxicam in rats

Ronise Martins Santiago, Tiago Zaminelli, Taysa B Bassani, Suelen L Boschen, Marcelo M S Lima, Cláudio Da Cunha, Roberto Andreatini, Maria A B F Vital

pp. 7–12 · DOI: 10.4103/0976-500X.149133 · Published 2015

Objective: To investigate the antidepressant-like effect of piroxicam with a focus on serotonergic neurotransmission. Materials and Methods: Rats were randomly distributed into the following groups: 0.9% saline control; …

Riociguat: Something new in pulmonary hypertension therapeutics?

Elangovan Shanmugam, Amrita Jena, Melvin George

pp. 3–6 · DOI: 10.4103/0976-500X.149132 · Published 2015

Pulmonary hypertension (PH) continues to be a disease that is associated with woeful outcomes. The search for an ideal drug molecule for PH led to the discovery of riociguat, which is a first-in-class drug molecule that …

Structural aberration in R282K genetic mutation and antiviral drug-resistant H7N9 bird flu

Somsri Wiwanitkit, Viroj Wiwanitkit

pp. 34–34 · DOI: 10.4103/0976-500X.149142 · Published 2015

The emerging H7N9 influenza is a significant infectious disease. This infection is classified as an atypical cross-species influenza infection. It is belongs to the bird flu group and can result in mortality. The underly…

Stevens-Johnson syndrome caused by cefepime?

Mavilia Luciano, Trifiro’ Caterina, Mercuri Santo Raffaele

pp. 35–36 · DOI: 10.4103/0976-500X.149143 · Published 2015

The clinical-dermatological picture and medical history allowed us to make an initial diagnosis of Stevens-Johnson syndrome (SJS), likely triggered by the administration of cefepime. SJS is a severe reaction to immunocom…

Pindolol augmentation of selective serotonin reuptake inhibitors and clomipramine for the treatment of obsessive-compulsive disorder: A meta-analysis

Sean A. Sassano-Higgins, Michele T. Pato

pp. 36–38 · DOI: 10.4103/0976-500X.149144 · Published 2015

Obsessive-compulsive disorder (OCD) is associated with an estimated lifetime prevalence of 2%. An estimated 50–80% of the patients are treatment-resistant, with either no response or a limited response to adequate trials…

Recurrence of atrial fibrillation after switching from brand to generic atenolol

Luca Gallelli, Francesca Maida, Orietta Staltari, Pierandrea Rende, Emilio Russo, Benedetto Caroleo

pp. 158–160 · DOI: 10.4103/0976-500X.149146 · Published 2014

Beta blockers are the initial treatment for rate control of supraventricular tachyarrhythmia in patients without a history of myocardial infarction or left ventricular dysfunction. In this article we report the recurrenc…

Isolated sinus tachycardia following reinitiation of risperidone in a patient with suspected autonomic hypersensitivity

Melanie J Grubisha, Jessica L Brennan, Antoine Douaihy

pp. 42–44 · DOI: 10.4103/0976-500X.149147 · Published 2015

The second generation antipsychotic risperidone is generally considered to have low cardiac adverse events, with an increased risk of ventricular arrhythmias being reported only rarely in literature. We report here the c…

Hypoglycemia, polycythemia and hyponatremia in a newborn exposed to nebivolol during pregnancy

Maria Giuseppa Sullo, Domenico Perri, Michelina Sibilio, Concetta Rafaniello, Annamaria Fucile

pp. 45–48 · DOI: 10.4103/0976-500X.149148 · Published 2015

Nebivolol is a third‑generation beta blocker that exerts selective antagonistic activity on β1 receptors. It has vasodilating properties that result from direct stimulation of endothelial nitric oxide synthase. Nebivolol…

A rare case modafinil dependence

Raman Krishnan, Krishnan Vengadaragava Chary

pp. 49–50 · DOI: 10.4103/0976-500X.149149 · Published 2015

Modafinil, a non-amphetamine psychostimulant, is indicated for narcolepsy, shift work sleep disorder and severe obstructive sleep apnea syndrome. Modafinil is prescribed at the dose of 100 mg once in a day or as two dose…

The association of oral contraceptive pills with increase in intraocular pressure: Time for pharmacovigilance to step in

Sangeeta Bhanwra, Kaza Ahluwalia

pp. 51–2 · DOI: 10.4103/0976-500X.149150 · Published 2015

Oral contraceptive pills (OCP) are very frequently used as a safe and effective method for birth control, in India and worldwide. However, the American Academy of Ophthalmology, in New Orleans, came out with a research s…

Macitentan: An important addition to the treatment of pulmonary arterial hypertension

Anjan Khadka, Dick B Singh Brashier, Anantharamu Tejus, Ashok Kumar Sharma

pp. 53–57 · DOI: 10.4103/0976-500X.149151 · Published 2015

Macitentan is an orphan drug for the treatment of pulmonary arterial hypertension (PAH). Endothelin‑1 (ET‑1) plays a critical role of pathophysiology of PAH. Macitentan, a new dual endothelin receptor antagonist, has rep…